Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab
- 28 August 2023
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 79 (6) , 1450-1458
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular CarcinomaNEJM Evidence, 2022
- Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic HepatocholangiocarcinomaLiver Cancer, 2022
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular CarcinomaCancer Discovery, 2019
- Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of ResponseGastroenterology, 2019
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)Annals of Oncology, 2018
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- cHCC‐CCAHepatology, 2018
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 TrialCancer Discovery, 2017
- Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)The Lancet Oncology, 2014